Venmax Drugs & Pharmaceuticals Ltd

Venmax Drugs & Pharmaceuticals Ltd (VENMAX) is a micro-cap Healthcare company valued at ₹14 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Venmax Drugs & Pharmaceuticals Ltd last traded at ₹14.4, modestly down 0.69% on the day.

Financial performance

The company's business has improved significantly, with annual revenue rising 890.1% to ₹8 crore, while annual net profit swung from a net loss of ₹0 crore to a profit of ₹0 crore. The latest quarter showed revenue up 105.0% year-on-year to ₹2 crore, and net profit increased 200.0% to ₹0 crore, though profitability remains at zero.

Valuation multiples

The stock trades at 68.6 times earnings, a premium to the Healthcare median of 32.0, 1.02 times book value.

Things to watch

The company's net profit margin improved 4.4 percentage points to 3.1%, but net profit remains at zero. The stock is 54.0% below its 52-week high, and the company's market cap is ₹17 crore, indicating limited liquidity and exposure.

Where it stands

Venmax Drugs & Pharmaceuticals Ltd reported a significant revenue growth of 890.1% annually, with the latest quarter showing a 105.0% increase in revenue. However, net profit remains at zero, and the stock is 54.0% below its 52-week high. The company's market cap is ₹17 crore, reflecting its micro-cap status.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.